Carbogen and nicotinamide as radiosensitizers in a murine mammary carcinoma using conventional and accelerated radiotherapy

International Journal of Radiation Oncology Biology Physics

Volumn 34, Issue 2, 1996, Pages 357-365

  Rojas, Anamaria ^a   Hirst, Victoria K ^a   Calvert, Angela S ^a   Johns, Helen ^a  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

Acceleration; ARCON; Carbogen; Fractionation; Me tastasis; Nicotinamide; Overall time; Radiotherapy; Rodents; Tumors

Indexed keywords

CARBOGEN; NICOTINAMIDE; RADIOSENSITIZING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOMA; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; GAS DIFFUSION; LINEAR ACCELERATOR; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIOSENSITIVITY; RADIOSENSITIZATION; TREATMENT OUTCOME;

EID: 0030065653     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/0360-3016(95)02087-X     Document Type: Article

References (32)

1. Bush, R. S.; Jenkin, R. D. T.; Allt, W. E. C.; Beale, F. A.; Bean, H.; Dembo, A. J.; Pringle, J. F. Definitive evidence for hypoxic cells influencing cure in cancer therapy. Br. J. Cancer 37:302-306; 1978.
2. Chaplin, D. J.; Horsman, M. R.; Aoki, D. S. Nicotinamide, Fluosol DA and carbogen: A strategy to reoxygenate acutely and chronically hypoxic cells in vivo. Br. J. Cancer 63:109-113; 1991.
3. Chaplin, D. J.; Horsman, M. R.; Siemann, D. W. Further evaluation of nicotinamide and carbogen as a strategy to reoxygenate hypoxic cells in vivo: Importance of nicotinamide dose and preirradiation breathing time. Br. J. Cancer 68:269-273; 1993.
4. Denekamp, J.; Hirst, D. G.; Stewart, F. A.; Terry, N. H. Is tumour radiosensitization by misonidazole a general phenomenon? Br. J. Cancer 41:1-9; 1980.
5. Dische, S.; Anderson, P. J.; Sealy, R.; Watson, E. R. Carcinoma of the cervix - Anaemia, radiotherapy and hyperbaric oxygen. Br. J. Radiol. 56:251-255; 1983.
6. Fowler, J. F. How worthwhile are short schedules in radiotherapy? A series of exploratory calculations. Radiother. Oncol. 18:165-181; 1990.
7. Gatenby, R. A.; Kessler, H. B.; Rosenblum, J. S.; Coia, L. R.; Moldofsky, P. J.; Hartz, W. H.; Broder, G. J. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 14:831-838; 1988.
8. Green, R. G. Subclinical pellagra: Its diagnosis and treatment. Schizophrenia 2:70-79; 1970.
9. Haustermans, K.; van der Kogel, A. J.; Vanacker, B.; van der Schueren, E. Influence of combined use of nicotinamide and carbogen on rat spinal cord radiation tolerance. Radiother. Oncol. 31:123-128; 1994.
10. Hawkins, D. R. Treatment of schizophrenia based on the medical model. J. Schizophr. 2:3-10; 1968.
11. Horiot, J. C.; Fur, R. L.; N'Guyen, T.; Chenal, C.; Schraub, S.; Alfonsi, S.; Gardani, G.; Bogaert, W. v. d.; Danczak, S. Hyperfractionated compared with conventional radiotherapy in oropharyngeal carcinoma: An EORTC randomized trial. Eur. J. Cancer 27:779-780; 1990.
12. Horsman, M. R.; Brown, J. M.; Hirst, V. K.; Lemmon, M. J.; Wood, P. J.; Overgaard, J. Mechanism of action of the selective tumor radiosensitizer nicotinamide. Int. J. Radiat. Oncol. Biol. Phys. 15:685-690; 1988.
13. Horsman, M. R.; Chaplin, D. J.; Brown, J. M. Radiosensitization by nicotinamide in vivo: A greater enhancement of tumor damage compared to that of normal tissues. Radiat. Res. 109:479-489; 1987.
14. Horsman, M. R.; Chaplin, D. J.; Brown, J. M. Tumor radiosensitization by nicotinamide: A result of improved perfusion and oxygenation. Radiât. Res. 118:139-150; 1989.
15. Horsman, M. R.; Hoyer, M.; Honess, D. J.; Dennis, I. F.; Overgaard, J. Nicotinamide pharmacokinetics in humans and mice: A comparative assessment and the implications for radiotherapy. Radiother. Oncol. 27:131-139; 1993.
16. Horsman, M. R.; Kristjansen, P. E.; Mizuno, M.; Christensen, K. L.; Chaplin, D. J.; Quistorff, B.; Overgaard, J. Biochemical and physiological changes induced by nicotinamide in a C3H mouse mammary carcinoma and CDF1 mice. Int. J. Radiat. Oncol. Biol. Phys. 22:451-454; 1992.
17. Hoskin, P. J.; Stratford, M. R. L. S.; Saunders, M. I.; Hall, D. W.; Dennis, M. F.; Rojas, A. Administration of nicotinamide during CHART: Pharmacokinetics, dose escalation and clinical toxicity. Int. J. Radiat. Oncol. Biol. Phys., in press.
18. Kjellen, E.; Joiner, M. C.; Collier, J. M.; Johns, H.; Rojas, A. A therapeutic benefit from combining normobaric carbogen or oxygen with nicotinamide in fractionated X-ray treatments. Radiother. Oncol. 22:81-91; 1991.
19. Overgaard, J. Importance of tumour hypoxia in radiotherapy. A meta-analysis of controlled clinical trials. Radiother. Oncol. 24:S64; 1992.
20. Overgaard, J.; Sand Hansen, H.; Lindelov, B.; Overgaard, M.; Jorgensen, K.; Rasmusson, B.; Berthelsen, A. Nimorazole as a hypoxic radiosensitizer in the treatment of supraglottic larynx and pharynx carcinoma. First report from the Danish Head and Neck Cancer Study (DAHANCA) protocol 5-85. Radiother. Oncol. 20(Suppl 1):143-149; 1991.
21. Peters, L. J.; Ang, K. K.; Thames, H. D. Accelerated fractionation in the radiation treatment of head and neck cancer. A critical comparison of different strategies. Acta Oncol. 27:185-194; 1988.
22. Rojas, A. ARCON: Accelerated radiotherapy with carbogen and nicotinamide. In: Denekamp, J., Hirst, D., eds. Radiation science - Of Molecules, Mice and Men. Br. J. Radiol. 24:174-178; 1992.
23. Rojas, A.; Carl, U.; Reghebi, K. Effect of normobaric oxygen on tumor radiosensitivity: Fractionated studies. Int. J. Radiat. Oncol. Biol. Phys. 18:547-553; 1990.
24. Rojas, A.; Hodgkiss, R. J.; Stratford, M. R. L.; Dennis, M. F.; Johns, H. Pharmacokinetics of varying doses of nicotinamide and tumour radiosensitisation with carbogen and nicotinamide: Clinical considerations. Br. J. Cancer 68:1115-1121; 1993.
25. Rojas, A.; Johns, H.; Russell, P. Should carbogen and nicotinamide be given throughout the full course of fractionated radiotherapy regimens? Int. J. Radiat. Oncol. Biol. Phys. 27:1101-1105; 1993.
26. Rojas, A.; Joiner, M. C.; Denekamp J. Extrapolations from laboratory and preclinical studies for the use of carbogen and nicotinamide in radiotherapy. Radiother. Oncol. 24:123-124; 1992.
27. Stratford, M. R.; Dennis, M. F. Pharmacokinetics and biochemistry studies on nicotinamide in the mouse. Cancer Chemother. Pharmacol. 34:399-404; 1994.
28. Stratford, M. R.; Dennis, M. F.; Saunders, M. I.; Hoskin, P.; Hodgkiss, R. J.; Rojas, A. Nicotinamide pharmacokinetics in volunteers and patients undergoing palliative radiotherapy. Acta Oncol., in press.
29. Stratford, M. R.; Rojas, A.; Hall, D. W.; Dennis, M. F.; Dische, S.; Joiner, M. C.; Hodgkiss, R. J. Pharmacokinetics of nicotinamide and its effect on blood pressure, pulse and body temperature in normal human volunteers. Radiother. Oncol. 25:37-42; 1992.
30. Withers, H. R.; Taylor, J. M.; Maciejewski, B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol. 27:131-146; 1988.
31. Zackheim, H. S.; Vasily, D. B.; Westphal, M. L.; Hastings, C. W. Reactions to niacinamide. J. Am. Acad. Dermatol. 4:736-737; 1981.
32. Zackrisson, B.; Franzén, L.; Henriksson, R.; Littbrand, B.; Stratford, M. R. L.; Dennis, M.; Rojas, A.; Denekamp, J. Acute effects of accelerated radiotherapy in combination with carbogen breathing and nicotinamide (ARCON). Acta Oncol. 33:377-381; 1994.